Business Standard

Biocon shares slump over 4% as profit declines 42% in March quarter

The company's revenue, however, saw a muted growth of 6 per cent as compared to Q4 of FY19

Biocon likely to channelise investments towards non-insulin biologics
Premium

Biocon's Biologics segment reported a de-growth of 21 per cent during the quarter

SI Reporter New Delhi
Shares of Biocon Limited dipped 4.11 per cent to Rs 321.50 on the BSE on Friday after the biotechnology major's net profit declined 42.2 per cent year-on-year (YoY) to Rs 123 crore in the fourth quarter of FY20 (Q4FY20).

The firm's profit before tax (PBT) declined 28.2 per cent to Rs 204 crore during the quarter when compared with the corresponding quarter of previous financial year. The company’s revenue, however, saw a muted growth of 6 per cent as compared to Q4 of FY19, according to a BSE filing by the company.

“Q4FY20 witnessed a muted growth of 6 per

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in